# An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

> **NCT06936787** · PHASE1 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 21 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** IGT001

## Key facts

- **NCT ID:** NCT06936787
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-20
- **Primary completion:** 2025-12-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06936787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06936787, "An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06936787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*